Aeglea Biotherapeutics , an Austin, Texas-based biopharmaceutical company focused on treating tumor metabolism, raised $44m in Series B funding.
The round was led by existing backers Lilly Ventures and Novartis Venture Fund with participation from UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.
The company intends to use the funds for the continued development of its pipeline of engineered human enzymes that target diseases at the extremes of abnormal metabolism.
Led by David G. Lowe, Ph.D., co-founder, President and Chief Executive Officer, Aeglea develops engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.
Its pipeline includes AEB1102, which we expect will enter into clinical trials in both hyperargininemia and cancer.
In addition, three additional drug candidates are in pre-clinical development:
– AEB4104, which degrades homocystine, is being evaluated as a potential treatment for the inborn error of metabolism homocystinuria;
– AEB3103, which degrades cysteine/cysteine, is being evaluated for its ability to increase oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies; and
– AEB2109, which degrades methionine, is being evaluated for the treatment of solid tumors.